A Study to Investigate LYL845 in Adults With Solid Tumors
Public ClinicalTrials.gov record NCT05573035. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Study to Assess the Safety and Efficacy of LYL845 in Adults With Relapsed and/or Refractory Metastatic or Locally Advanced Melanoma and Selected Solid Tumor Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an open-label, multi-center, dose-escalation study with expansion cohorts, designed to evaluate the safety and anti-tumor activity of LYL845, an epigenetically reprogrammed tumor infiltrating lymphocyte (TIL) therapy, in participants with relapsed or refractory (R/R) metastatic or locally advanced melanoma, non-small cell lung cancer (NSCLC), and colorectal cancer (CRC).
Study identification
- NCT ID
- NCT05573035
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 39 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 19, 2022 (Actual)
- Primary completion
- Jan 9, 2025 (Actual)
- Completion
- Jan 9, 2025 (Actual)
- Last update posted
- Jul 1, 2025
2022 – 2025
United States locations
- U.S. sites
- 18
- U.S. states
- 14
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UC Davis Coomprehensive Cancer Center | Sacramento | California | 95817 | — |
| UCLA Medical Center | Santa Monica | California | 90404 | — |
| Stanford University | Stanford | California | 94305 | — |
| Yale Cancer Center, Yale University | New Haven | Connecticut | 06511 | — |
| Georgetown University | Washington D.C. | District of Columbia | 20007 | — |
| University of Iowa Hospitals and Clinics | Iowa City | Iowa | 52242 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Mayo Clinic Comprehensive Cancer Center | Rochester | Minnesota | 55905 | — |
| Hackensack Meridian Health Inc | Hackensack | New Jersey | 07601 | — |
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08901 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| Ohio State University Medical Center | Columbus | Ohio | 43210 | — |
| Oregon Health Sciences University | Portland | Oregon | 97239 | — |
| Allegheny General Hospital | Pittsburgh | Pennsylvania | 15224 | — |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75235 | — |
| Huntsman Cancer Institute at University of Utah | Salt Lake City | Utah | 84112 | — |
| Fred Hutchinson Cancer Center | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05573035, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 1, 2025 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05573035 live on ClinicalTrials.gov.